Cargando…

Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran—An ongoing clinical conundrum

A 47‐year‐old woman with acute intermittent porphyria (AIP) has had recurring symptoms after achieving biochemical normalization of her urinary 5‐aminolevulinic acid (ALA), porphobilinogen (PBG), and total porphyrins with givosiran. She has had normal liver tests, mildly decreased renal function, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Christopher D., Faust, Denise, Bonkovsky, Herbert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981411/ https://www.ncbi.nlm.nih.gov/pubmed/36873084 http://dx.doi.org/10.1002/jmd2.12354

Ejemplares similares

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria
por: Ma, Christopher D., et al.
Publicado: (2022)

Acute intermittent porphyria, givosiran, and homocysteine
por: Fontanellas, Antonio, et al.
Publicado: (2021)

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
por: Majeed, Chaudry Nasir, et al.
Publicado: (2022)

Benefits of prophylactic heme therapy in severe acute intermittent porphyria
por: Yarra, Pradeep, et al.
Publicado: (2019)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021)

Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review
por: Patel, Priyansh, et al.
Publicado: (2023)

Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria
por: Graff, Erica, et al.
Publicado: (2022)

PB2559: VARIEGATE PORPHYRIA CONFIRMED BY NGS AND TREATED WITH GIVOSIRAN - CASE PRESENTATION
por: Georgescu, Georgeta Daniela
Publicado: (2023)

Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
por: Petrides, Petro E., et al.
Publicado: (2021)

Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria
por: Lee, Jongtae, et al.
Publicado: (2023)

Acute intermittent porphyria
por: Syal, Kartik, et al.
Publicado: (2015)

Intermittent Acute Porphyria
por: Macleod, J. G., et al.
Publicado: (1953)

Acute Hepatic Porphyrias: Review and Recent Progress
por: Wang, Bruce, et al.
Publicado: (2018)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Feigning Acute Intermittent Porphyria
por: Elkhatib, Rania, et al.
Publicado: (2014)

Acute Intermittent Porphyria’s Symptoms and Management: A Narrative Review
por: Kizilaslan, Esma Z, et al.
Publicado: (2023)

Evaluating the Patient Reported Outcomes Measurement Information System Scales in Acute Intermittent Porphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

Cardiac calcification in acute intermittent porphyria
por: Ghatak, Tanmoy, et al.
Publicado: (2011)

Acute Intermittent Porphyria in Argentina: An Update
por: Cerbino, Gabriela Nora, et al.
Publicado: (2015)

Liver Transplantation for Acute Intermittent Porphyria
por: Lissing, Mattias, et al.
Publicado: (2021)

Mortality in Pedigrees with Acute Intermittent Porphyria
por: Neeleman, Rochus, et al.
Publicado: (2022)

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review
por: Wang, Bruce, et al.
Publicado: (2023)

Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias
por: Besur, Siddesh, et al.
Publicado: (2014)

Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients
por: Buendía-Martínez, Juan, et al.
Publicado: (2021)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

An update of clinical management of acute intermittent porphyria
por: Pischik, Elena, et al.
Publicado: (2015)

Acute Intermittent Porphyria: A Diagnostic Challenge
por: Vakili, Rahim, et al.
Publicado: (2016)

Effect of Menstrual Cycle on Acute Intermittent Porphyria
por: Júnior, V. R. Souza, et al.
Publicado: (2017)

Medical and financial burden of acute intermittent porphyria
por: Neeleman, Rochus A., et al.
Publicado: (2018)

Dental and Periodontal Health in Acute Intermittent Porphyria
por: Storjord, Elin, et al.
Publicado: (2022)

Biomarkers that predict attacks of acute intermittent porphyria
por: Takata, Tadayuki, et al.
Publicado: (2022)

Takotsubo Cardiomyopathy Triggered by Acute Intermittent Porphyria
por: Alzahrani, Talal
Publicado: (2023)

An analysis of six cases of acute intermittent porphyria (AIP)
por: Ghosh, Soumitra, et al.
Publicado: (2006)

Acute intermittent porphyria: Diagnostic dilemma and treatment options
por: Kaur, Mohan Deep, et al.
Publicado: (2015)

Acute Intermittent Porphyria: A Diagnostic Challenge for Endocrinologist
por: Yuan, Tao, et al.
Publicado: (2015)

Acute intermittent porphyria after right hemi-colectomy()
por: Alshammary, Shadi, et al.
Publicado: (2017)

Acute intermittent porphyria: a test of clinical acumen
por: Dhital, Rashmi, et al.
Publicado: (2017)

Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria
por: Fu, Yibao, et al.
Publicado: (2019)

A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria
por: Bustad, Helene J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mhn8pp1fggc7np9ouk1e69nn8q